Provided by UCL School of Pharmacy University College London (UCL) supported European Paediatric Formulation Initiative’s (EuPFI) mission to promote and facilitate safe medicines for children by hosting the workshop at UCL School of Pharmacy, with the aim of finding an optimal path towards the correct oral dosing of all paediatric patients with dosing syringes and […]

by Nick Paul Taylor The FDA has lifted a partial clinical hold from Epizyme’s tazemetostat. Epizyme got the green light to resume enrollment in trials of the EZH2 inhibitor after showing the FDA data on the risk of secondary malignancies. Tazemetostat ran into trouble in April when a pediatric cancer patient taking the drug developed a secondary T-cell […]

by Amirah Al Idrus GlaxoSmithKline and Valeant marketed their epilepsy drug ezogabine for just six years before pulling it for “commercial reasons.” Now, Xenon Pharmaceuticals is taking a stab at repurposing the drug for a rare, difficult-to-treat form of pediatric epilepsy caused by a genetic mutation. Ezogabine was originally approved in 2011 as an add-on treatment […]

KinderPharm heads to the Joint EFGCP & DIA Better Medicines for Children Conference in Brussels this month. The EFGCP Children Medicine Working Party in collaboration with DIA and Regulators will take stock of the progress achieved in the pediatric field after ten years of Pediatric Regulation. This year’s conference focuses on what could be done […]

The U.S. Food and Drug Administration announced today that it has awarded five grants totaling up to $6 million per year over the next five years to Pediatric Device Consortia (PDC) across the country that will provide advice and support services to innovators of children’s medical devices. The program aims to enhance the development, production […]